Pediatric Liposarcoma
- Author: Vikramjit S Kanwar, MD, MBA, MRCP(UK), FAAP; Chief Editor: Max J Coppes, MD, PhD, MBA more...
Background
Liposarcoma is one of the least frequent nonrhabdomyosarcoma soft tissue sarcomas to occur in childhood; it comprises less than 5% of all soft tissue sarcomas in childhood.[1, 2] Surgical excision is the primary treatment, and prognosis depends on the histologic subtype and degree of resection. For patients with residual disease, radiotherapy has been used.[1]
Pathophysiology
Liposarcoma is a lipogenic tumor of large deep-seated connective tissue spaces. The 3 major locations in which liposarcomas are found are the lower extremities, the retroperitoneal region, and the shoulder area. The favored sites of occurrence in the lower extremities include the popliteal fossa and medial thigh. The most common retroperitoneal location is the perineal region. Occasionally, tumors may originate in the subcutis of shoulder, neck, and facial areas. Children tend to have a higher incidence of lower extremity tumors.[3]
Well-differentiated liposarcoma has amplification of region 12q13–15, which includes the genes MDM2 and CDK4.[4]
Myxoid liposarcoma has the translocation t(12;16)(q13;p11.2). This involves fusion of the transcription factor gene CHOP, which is essential for adipocytic differentiation, to the translocated in liposarcoma (TLS) gene on chromosome 16.[5] In about 2% of cases, a variant translocation t(12;22)(q13;q12) that involves fusion of CHOP with the EWS gene on chromosome 22 is noted. These cytogenetic abnormalities have also been reported in the more aggressive round-cell liposarcoma; myxoid and round-cell liposarcoma form a spectrum with regard to disease aggressiveness.[6]
Pleomorphic liposarcoma lacks identifiable translocations or gene amplification and was characterized by its clinical and pathologic aggressiveness. The introduction of molecular biological analysis suggests that many of these tumors express MDM2 and CDK4 and may better be described as dedifferentiated liposarcoma.[7]
In retrospective review of 331 liposarcoma samples, the use of molecular techniques in addition to standard histology resulted in a change in the type of liposarcoma diagnosed in approximately one-quarter of patients.[7]
Epidemiology
Frequency
United States
In children, liposarcomas are rare and comprise fewer than 5% of soft tissue sarcomas.
Overall, less than 150 cases of childhood liposarcoma have been reported in the literature, usually in the second decade of life.[8, 9] At a large New York Cancer Hospital, 18 cases of liposarcoma were reported in patients aged 22 years or younger over a period of 4 decades.[10] A multi-institutional study reviewed 82 patients younger than 22 years diagnosed over a 27-year period.[11]
Mortality/Morbidity
Due to its rarity, survival data for liposarcoma patients are often extrapolated from small series or from adult data. As with other childhood nonrhabdomyosarcoma soft tissue sarcomas, outcome is linked to various prognostic factors, including stage and grade. Complete surgical resection is crucial. The estimated 5-year overall survival rates are impacted by histologic subtype and are as follows:[7]
- Pleomorphic tumors - 40%
- Round-cell tumors - 40%
- Myxoid tumors - 80%
- Well-differentiated tumors - 80-100%
Local recurrence following resection is common and may be avoided by wide excision or adjuvant radiation. Thus, an extremity location, which allows aggressive surgery, is a favorable prognostic feature as opposed to a retroperitoneal location.
Metastatic spread varies but commonly occurs to the lungs in high-grade pleomorphic tumors.[12] Lymphatic spread is not seen. Myxoid liposarcoma is often considered intermediate grade but may still metastasize in 10-35% patients, sometimes to extrapulmonary soft tissue sites, such as the retroperitoneum or chest wall[13] or even brain and spine.[14]
Race
No racial predilection is apparent.
Sex
In the several small series reported, gender predominance varies; assessing an accurate male-to-female ratio is not currently possible.
Age
Overall, the average age at presentation is 50 years. Liposarcomas are rarely seen in the teenage years and are almost never found in patients younger than 8 years. Earlier reports of liposarcoma in infancy are now mostly thought to be lipoblastomatosis.[3]
Marcus KC, Grier HE, Shamberger RC, Gebhardt MC, Perez-Atayde A, Silver B. Childhood soft tissue sarcoma: a 20-year experience. J Pediatr. Oct 1997;131(4):603-7. [Medline].
Spunt SL, Poquette CA, Hurt YS, et al. Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St Jude Children's Research Hospital. J Clin Oncol. Dec 1999;17(12):3697-705. [Medline].
Shmookler BM, Enzinger FM. Liposarcoma occurring in children. An analysis of 17 cases and review of the literature. Cancer. Aug 1 1983;52(3):567-74. [Medline].
Italiano A, Cardot N, Dupre F, et al. Gains and complex rearrangements of the 12q13-15 chromosomal region in ordinary lipomas: the "missing link" between lipomas and liposarcomas?. Int J Cancer. Jul 15 2007;121(2):308-15. [Medline].
Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature. Jun 17 1993;363(6430):640-4. [Medline].
Fiore M, Grosso F, Lo Vullo S, et al. Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution. Cancer. Jun 15 2007;109(12):2522-31. [Medline].
de Vreeze RS, de Jong D, Nederlof PM, et al. Added Value of Molecular Biological Analysis in Diagnosis and Clinical Management of Liposarcoma: A 30-Year Single-Institution Experience. Ann Surg Oncol. Mar 2010;17(3):686-93. [Medline].
Castleberry RP, Kelly DR, Wilson ER, et al. Childhood liposarcoma. Report of a case and review of the literature. Cancer. Aug 1 1984;54(3):579-84. [Medline].
Ferrari A, Casanova M, Spreafico F, et al. Childhood liposarcoma: a single-institutional twenty-year experience. Pediatr Hematol Oncol. Sep-Oct 1999;16(5):415-21. [Medline].
La Quaglia MP, Spiro SA, Ghavimi F, Hajdu SI, Meyers P, Exelby PR. Liposarcoma in patients younger than or equal to 22 years of age. Cancer. Nov 15 1993;72(10):3114-9. [Medline].
Alaggio R, Coffin CM, Weiss SW, et al. Liposarcomas in young patients: a study of 82 cases occurring in patients younger than 22 years of age. Am J Surg Pathol. May 2009;33(5):645-58. [Medline].
Gronchi A, Casali PG, Fiore M, et al. Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. Cancer. Jun 1 2004;100(11):2448-55. [Medline].
Cheng EY, Springfield DS, Mankin HJ. Frequent incidence of extrapulmonary sites of initial metastasis in patients with liposarcoma. Cancer. Mar 1 1995;75(5):1120-7. [Medline].
Schwab JH, Boland PJ, Antonescu C, Bilsky MH, Healey JH. Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging. Cancer. Oct 15 2007;110(8):1815-22. [Medline].
Antonescu CR, Elahi A, Humphrey M, et al. Specificity of TLS-CHOP rearrangement for classic myxoid/round cell liposarcoma: absence in predominantly myxoid well-differentiated liposarcomas. J Mol Diagn. Aug 2000;2(3):132-8. [Medline]. [Full Text].
Brandal P, Bjerkehagen B, Heim S. Rearrangement of chromosomal region 8q11-13 in lipomatous tumours: correlation with lipoblastoma morphology. J Pathol. Feb 2006;208(3):388-94. [Medline].
Song T, Shen J, Liang BL, Mai WW, Li Y, Guo HC. Retroperitoneal liposarcoma: MR characteristics and pathological correlative analysis. Abdom Imaging. Sep-Oct 2007;32(5):668-74. [Medline].
Brenner W, Eary JF, Hwang W, Vernon C, Conrad EU. Risk assessment in liposarcoma patients based on FDG PET imaging. Eur J Nucl Med Mol Imaging. Nov 2006;33(11):1290-5. [Medline].
Enzinger FM, Weiss SW. Liposarcoma. In: Enzinger F, Weiss S, eds. Soft Tissue Tumors. St Louis, MO: Mosby; 1995:431-66.
Raaf JH, Ragsdale BD. Surgical management of liposarcoma. In: Bogumil GP, Fleegler EJ, eds. Tumors of the Hand and Upper Limb. 1993.
Jones RL, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. Dec 2005;41(18):2853-60. [Medline].
Cecchetto G, Alaggio R, Dall'Igna P, et al. Localized unresectable non-rhabdo soft tissue sarcomas of the extremities in pediatric age: results from the Italian studies. Cancer. Nov 1 2005;104(9):2006-12. [Medline].
Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. Sep 1 2009;27(25):4188-96. [Medline].
Mahmood ST, Agresta S, Vigil C, et al. Phase II study of sunitinib malate, a multi-targeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on 3 prevalent histologies: Leiomyosarcoma, liposarcoma, and malignant fibrous histiocytoma. Int J Cancer. Dec 10 2010;[Medline].
Print
